Recent Advances in Treatment Strategies for Atopic Dermatitis

Overview

Journal Drugs

Specialty Pharmacology

Date 2004 Nov 13

PMID 15537368

Citations 4

Authors

Thomas Christian Roos

Stefan Geuer

Sabine Roos

Harald Brost

Affiliations

Soon will be listed here.

Abstract

A wide range of different therapeutic regimens are used for atopic dermatitis. Although many treatment modalities are well established worldwide among clinicians, only the minority of these therapy recommendations are based on results of randomised controlled trials (RCTs). To close the gap between such 'generally' recommended therapies and therapies that are based on data from controlled trials, this review focuses not only on the pharmacological and clinical aspects of the currently proven agents, but also on the advantages and disadvantages of therapies that have not yet been completely tested.A review of the available literature concerning the pharmacological profile and also the level of evidence of therapeutic efficacy of all currently known topical and systemic agents for the treatment of atopic dermatitis reveals a large gap between the knowledge concerning the pharmacological action in vitro and the evidence of clinical efficacy in many cases. We agree with the conclusion of previous reviews that numerous therapies for atopic dermatitis urgently require more independent RCTs and especially comparative trials (e.g. corticosteroids vs calcineurin inhibitors). These are required in order to facilitate the choice of therapeutic strategy for the individual treatment of atopic dermatitis, with its broad spectrum of clinical manifestations and potential complications in adult patients and, particularly, in children.Finally, we also review preclinical trials with several new drugs. Immunomodulators appear to promise a new dimension for the future of therapy for atopic dermatitis, especially for severe and otherwise refractory forms or as alternatives to corticosteroids, that is, to treat facial atopic eczema without the risk of adverse effects.

Citing Articles

Specific allergen immunotherapy for the treatment of atopic eczema.

Tam H, Calderon M, Manikam L, Nankervis H, Garcia Nunez I, Williams H Cochrane Database Syst Rev. 2016; 2:CD008774.

PMID: 26871981 PMC: 8761476. DOI: 10.1002/14651858.CD008774.pub2.

Investigation of the stabilizing effects of antioxidants and benzophenone-3 on desonide photostability.

Rosa P, Snovarski Salla A, de Bona da Silva C, Rolim C, Adams A AAPS PharmSciTech. 2014; 15(5):1155-62.

PMID: 24871554 PMC: 4179652. DOI: 10.1208/s12249-014-0149-0.

Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients.

Hon K, Pong N, Wang S, Lee V, Luk N, Leung T Drugs R D. 2013; 13(1):37-42.

PMID: 23456759 PMC: 3627015. DOI: 10.1007/s40268-013-0004-x.

Unraveling the mystery of vernix caseosa.

Singh G, Archana G Indian J Dermatol. 2009; 53(2):54-60.

PMID: 19881987 PMC: 2763724. DOI: 10.4103/0019-5154.41645.

References

Matricardi P, Rosmini F, Riondino S, Fortini M, Ferrigno L, Rapicetta M . Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ. 2000; 320(7232):412-7. PMC: 27285. DOI: 10.1136/bmj.320.7232.412. View

Kimata H . Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol. 1999; 82(3):293-5. DOI: 10.1016/S1081-1206(10)62611-7. View

Spencer J, Gonzalez 3rd L, Barnhart D . Medications in the breast-feeding mother. Am Fam Physician. 2001; 64(1):119-26. View

Sudilovsky A, Muir J, BOCOBO F . A comparison of single and multiple applications of halcinonide cream. Int J Dermatol. 1981; 20(9):609-13. DOI: 10.1111/j.1365-4362.1981.tb00847.x. View

Grandel K, Farr R, Wanderer A, Eisenstadt T, Wasserman S . Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med. 1985; 313(7):405-9. DOI: 10.1056/NEJM198508153130702. View

Hepburn D, Aeling J, Weston W . A reappraisal of topical steroid potency. Pediatr Dermatol. 1996; 13(3):239-45. DOI: 10.1111/j.1525-1470.1996.tb01211.x. View

Boguniewicz M, Jaffe H, Izu A, Sullivan M, York D, Geha R . Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med. 1990; 88(4):365-70. DOI: 10.1016/0002-9343(90)90490-5. View

Veien N, Kaaber K, Larsen P, Nielsen A, Thestrup-Pedersen K . Ranitidine treatment of hand eczema in patients with atopic dermatitis: a double-blind, placebo-controlled trial. J Am Acad Dermatol. 1995; 32(6):1056-7. DOI: 10.1016/0190-9622(95)91363-7. View

de Prost Y, Teillac D, Paquez F, Carrugi L, Bachelez H, Touraine R . Placebo-controlled trial of topical cyclosporin in severe alopecia areata. Lancet. 1986; 2(8510):803-4. DOI: 10.1016/s0140-6736(86)90315-6. View

10.

Schultz Larsen F, Diepgen T, Svensson A . The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol. 1996; 34(5 Pt 1):760-4. DOI: 10.1016/s0190-9622(96)90009-2. View

11.

Abeck D, Andersson T, Grosshans E, Jablonska S, Kragballe K, Vahlquist A . Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. Acta Derm Venereol. 1997; 77(6):449-51. DOI: 10.2340/0001555577449451. View

12.

Van Bever H, Stevens W . Nedocromil sodium cream in the treatment of atopic dermatitis. Eur J Pediatr. 1989; 149(1):74. DOI: 10.1007/BF02024342. View

13.

Lilja G, Wickman M . Allergy--atopy--hypersensitivity--a matter of definition. Allergy. 1998; 53(11):1011-2. DOI: 10.1111/j.1398-9995.1998.tb03810.x. View

14.

Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M . Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002; 205(3):271-7. DOI: 10.1159/000065863. View

15.

Langeland T, Fagertun H, Larsen S . Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy. 1994; 49(1):22-6. DOI: 10.1111/j.1398-9995.1994.tb00768.x. View

16.

Muller U, Akdis C, Fricker M, Akdis M, Blesken T, Bettens F . Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998; 101(6 Pt 1):747-54. DOI: 10.1016/S0091-6749(98)70402-6. View

17.

Bernstein J, Grinzi R . Butorphanol-induced pruritus antagonized by naloxone. J Am Acad Dermatol. 1981; 5(2):227-8. DOI: 10.1016/s0190-9622(81)80079-5. View

18.

Kilpelainen M, Terho E, Helenius H, Koskenvuo M . Farm environment in childhood prevents the development of allergies. Clin Exp Allergy. 2000; 30(2):201-8. DOI: 10.1046/j.1365-2222.2000.00800.x. View

19.

Stoenescu M . "Atopy", "allergy" and "hypersensitivity" are--explicitly or implicitly--defined in different ways. Allergy. 1999; 54(6):640-2. DOI: 10.1034/j.1398-9995.1999.00214.x. View

20.

BLEEHEN S, Chu A, HAMANN I, Holden C, Hunter J, Marks R . Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995; 133(4):592-7. DOI: 10.1111/j.1365-2133.1995.tb02711.x. View